PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Cystitis
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Trial Timeline
Aug 1, 2008 → Jan 1, 2010
NCT ID
NCT00739739About PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685 is a phase 2 stage product being developed by Pfizer for Interstitial Cystitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00739739. Target conditions include Interstitial Cystitis, Painful Bladder Syndrome.
What happened to similar drugs?
1 of 5 similar drugs in Interstitial Cystitis were approved
Approved (1) Terminated (2) Active (3)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00739739 | Phase 2 | Completed |
Competing Products
20 competing products in Interstitial Cystitis